Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

The Doodle shows how the parabola changes with different numbers, making learning math fun and interactive for students.,, ...

Sabre is regaining ground after a tough year, President and CEO Kurt Ekert told Skift after the company’s third-quarter ...

Find out how GDP can help measure the health of a country’s economy Michael Boyle is an experienced financial professional with more than 10 years working with financial planning, derivatives, ...

TRINITY HALL and Harpsden both recorded wins in the Henley and District Billiards League last week. But it appears Earley Home Guard now have an insurmountable lead at the top of the table, having ...

SIXTH Form at the Abbey School is very much based around the idea of a community, with upper and lower sixth girls mixing both in the centre and in tutor groups. At the core of the sixth form is a ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.